KG013 / Kaigene, Celltrion - LARVOL DELTA

Kaigene Enters into Exclusive Global Licensing Agreement with Celltrion for Next-Generation Anti-APRIL Antibody KG013 (PRNewswire) - "Under the agreement, Kaigene grants Celltrion exclusive worldwide rights to develop and commercialize KG013. Kaigene is eligible to receive up to $580.5 million (approximately KRW 769 billion) in total consideration comprising an upfront payment and development, regulatory and commercialization milestone payments, with milestone payments contingent on achieving the relevant objectives. Royalties on net sales are payable separately. Kaigene retains the option to participate in co-marketing in South Korea, subject to the terms of the agreement...The initial indication is IgAN, a progressive kidney disease in which pathogenic IgA-containing immune complexes accumulate in the kidneys and cause inflammation and damage."

Licensing / partnership • IgA Nephropathy